Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information’s latest report, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.
Market Drivers & Opportunities
mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.
With leading companies such as Abbott, Cepheid, bioMérieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:
- What is the size and projected growth of the mPOC market?
- Which companies are leading the market, and how are they positioned?
- How is mPOC impacting traditional laboratory-based molecular testing?
- What regions and disease segments present the greatest opportunities?
This report offers detailed segmentation of the mPOC market, including:
- Market Sizing & Forecasts (2024-2029) – Revenue projections by technology, region, and disease area.
- Competitive Analysis – Market share breakdowns and insights into leading companies.
- Geographic Trends – Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
- Technology & Regulatory Landscape – Overview of CLIA-waived and moderate-complexity molecular platforms.
Scope
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029 provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.
This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.
A Decade of mPOC Research Expertise
Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, offers critical insights to help you navigate and capitalize on this fast-growing segment.
- CHAPTER 1: EXECUTIVE SUMMARY
- Figure 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
- Figure 1-2: Near Patient Molecular Systems Market, 2024-2029 ($ million)
- WHERE IS MOLECULAR POINT-OF-CARE IN 2025?
- Table 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
- MOLECULAR POINT-OF-CARE MARKET ANALYSIS
- Table 1-2: Molecular Point-of-Care Market Growth, 2024-2029 (%)
- Figure 1-3: Molecular Point-of-Care Market, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
- Market Observations
- “Near-Patient” Molecular Systems Market
- Table 1-3: Near Patient Molecular Systems Market, 2024-2029 ($ million)
- Table 1-4: Near Patient Molecular Systems Market Growth, 2024-2029 (%)
- Table 1-5: mPOC and Near-Patient Market, 2024-2029 ($ million)
- Figure 1-4: mPOC and Near-Patient Market, 2024-2029 ($ million)
- CURRENT TRENDS
- Molecular Point-of-Care Diagnostics Defined
- Usage of Molecular Point-of-Care
- Leading mPOC Platforms
- Table 1-6: Molecular POC Diagnostic Platforms and Technologies
- TRENDS
- SCOPE AND METHODOLOGY
- CHAPTER 2: MOLECULAR POINT-OF-CARE MARKET DEVELOPMENT AND TRENDS
- COVID-19 AND MOLECULAR POC
- Table 2-1: Molecular POC COVID-19 Emergency Authorizations
- CDC Initial Response, Long Term Situation
- COVID-19’s Unique Challenge
- BARDA Directs Funding to mPOC
- REGULATORY DEVELOPMENTS
- CONSORTIA, FUNDING, PRIZES
- DEALS
- Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
- ADVANTAGES AND DISADVANTAGES OF MOLECULAR POINT-OF-CARE
- Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
- JUSTIFICATION: THE SENSITIVITY/SPECIFICITY ARGUMENT
- NEW SYSTEMS AND MENU EXPANSION
- New Systems Introduced in Development
- Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
- STI Continues to Be a Growth Area
- DEALS, INVESTMENT IN MPOC SYSTEMS
- Roche Acquires LumiraDx for up to $350 Million
- Thermo Acquires Mesa Biotech
- CHINA AS A POC MARKET
- COMMON TESTS AND ANALYTES IN POC DIAGNOSTICS
- COMPONENT TECHNOLOGIES OF MOLECULAR POINT-OF-CARE DIAGNOSTICS
- Microfluidics
- qPCR
- Microarrays
- Isothermal Amplification
- Test Automation
- Primers and Probes
- Detection
- Next-Generation Sequencing
- Molecular Diagnostics
- Real-Time PCR (qPCR)
- Isothermal Amplification Methods
- Loop-Mediated Isothermal Amplification (LAMP)
- Nicking Enzyme Amplification Reaction (NEAR)
- Strand Displacement Amplification (SDA)
- Helicase Dependent Amplification (HDA)
- Nucleic Acid Sequence-Based Amplification (NASBA)
- Transcription-Mediated Amplification (TMA)
- Cross Priming Amplification (CPA)
- Line Probe Assays
- APPLICATIONS AND POTENTIAL APPLICATIONS FOR MOLECULAR POINT-OF-CARE
- Major Testing Applications for Molecular POC Diagnostics
- Influenza
- Reclassification of RIDTs
- Hospital-Acquired Infections (HAIs)
- Strep A
- Respiratory Syncytial Virus (RSV)
- Emerging Applications
- Zika
- Other Respiratory Infections
- Group B Streptococcus
- Human Papillomavirus
- Herpes Simplex Virus
- Vaginitis
- Tuberculosis
- Malaria
- Other Tropical and Neglected Diseases
- Cancer
- EUROPEAN DEVICE REGULATIONS
- CHAPTER 3: MARKET ANALYSIS
- MOLECULAR POINT-OF-CARE MARKET ANALYSIS
- Table 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
- Figure 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
- Regional Shares
- Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Figure 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Figure 3-3: Global Molecular Point-of-Care Market Share, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Breakout by Disease Area
- Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
- Figure 3-4: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
- Figure 3-5: Breakout of Molecular Point-of-Care Market Share, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
- “NEAR PATIENT MOLECULAR” MARKET
- Table 3-4: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
- Figure 3-6: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million)
- Vendor Market Share for Near Patient Molecular Testing
- Table 3-5: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMérieux, Cepheid, Roche, Other]
- Figure 3-7: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMérieux, Cepheid, Roche, Other]
- CHAPTER 4: COMPANY PROFILES
- ABBOTT LABORATORIES
- AIDIAN OY
- AKONNI BIOSYSTEMS
- BINX HEALTH, INC.
- BIOCARTIS NV
- BIOMÉRIEUX SA
- Table 4-1: bioMérieux FilmArray Est. Systems per Quarter, Q4 '18-Q4 '24
- Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q4 2024
- CEPHEID (DANAHER)
- Molecular Healthcare-Acquired Infection (HAI) Testing
- Molecular Sexual Health and Women’s Health Testing
- Molecular Critical Infectious Disease Testing
- Molecular Oncology/Genetics Testing
- CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
- CURETIS NV (OPGEN)
- DIASORIN S.P.A
- GENMARK DIAGNOSTICS (ROCHE)
- GREINER BIO-ONE GMBH
- LUCIRA HEALTH (PFIZER)
- MERIDIAN BIOSCIENCE, INC. (SD BIOSENSOR)
- MESA BIOTECH, INC. (THERMO)
- QIAGEN NV
- QUANTUMDX GROUP
- QUIDELORTHO CORPORATION
- ROCHE
- SEKISUI DIAGNOSTICS LLC
- T2 BIOSYSTEMS
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook